Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Under a Settlement Agreement entered into on October 11, 2011, Onyx and Bayer agreed to settle and dismiss all claims related to the complaint filed by Onyx…
Frames the settlement factually as resolution of the dispute — 'a deal has now been reached, and legal proceedings have been dropped' — without evaluating the…
FierceBiotech reported the speedy FDA approval of regorafenib at $9,350/month with analyst peak-sales expectations of $1.25B+, validating Bayer's decision to…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Bayer and Onyx restructured their global oncology collaboration: Bayer gained sole decision-making for regorafenib in exchange for $160M cash settlement and royalty on regorafenib. Bayer also bought out Onyx's Japan Nexavar royalty rights.
Assessment window: 10yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bayer AG / Onyx Pharmaceuticals (this deal) | 2011 | $160M | — |
| Bayer AG / Schering AG | 2006 | $21.5B | 79 |
| Bayer AG / BlueRock Therapeutics | 2002 | $600M | 79 |
| Bayer AG / Merck & Co., Inc. | 2014 | $14.2B | 71 |
| Bayer AG / Schering AG (residual squeeze-out) | 2007 | $985M | 69 |
| Bayer AG / Arvinas, Inc. | 2019 | $1.0B | 59 |
| Bayer AG / Merck & Co. Inc. | 2014 | $14.2B | 56 |
← Browse all deals · How we score deals
More: 2011 deals · Bayer AG deals · Oncology deals